Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record.

Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304

Heinemann, L., Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., Heise, T. · 1999 · Diabetic Medicine

Abstract

Summary: Aims To compare the pharmacokinetic and pharmacodynamic properties of subcutaneously injected NN304, a novel long‐acting insulin analogue, to NPH‐insulin during euglycaemic glucose clamps in 11 healthy volunteers. Methods On three study days NN304 was injected in three different doses (0.15, 0.3, 0.6 U/kg body weight), while NPH‐insulin (0.3 U/kg) was injected in identical dose on two other days. Results Injection of NN304 resulted in a linear and proportional increase in total NN304 concentrations (AUC 0–1440 min: 0.15 U/kg: 344 ± 43, 0.3 U/kg: 666 ± 82, 0.6 U/kg: 1295 ± 210 nmol/l; P < 0.001). Maximal concentrations (609 ± 140, 1046 ± 283, 2033 ± 460 pmol/l; P < 0.001) were reached after 4–6 h. The metabolic response (expressed as maximal glucose infusion rates (GIR)) induced by subcutaneous injection of NN304 did not show the pronounced peak seen with NPH‐insulin in an identical dose: GIR max 3.2 ± 1.1 vs. 4.4 ± 1.8 mg/kg/min (P < 0.05 for 0.3 U/kg NN304 vs. NPH‐insulin; mean of both study days with NPH‐insulin, all others not significant). NN304 also showed a slower onset of action, as indicated by a significantly higher t max (446 ± 162 vs. 359 ± 175 min) and lower AUC 0–240 min (0.5 ± 0.3 vs. 0.8 ± 0.4 g/kg/240 min; P < 0.05, respectively). The three different doses of NN304 induced a significantly different glucose consumption in the first 720 min after injection (AUC 0–720 min 1.1 ± 0.6, 1.9 ± 0.8, 1.7 ± 0.8 g/kg; P < 0.05 for 0.15 U/kg), but not over the whole study period (AUC 0–1440 min 1.8 ± 1.1, 3.1 ± 1.3, 2.8 ± 1.4 g/kg). Conclusions Injection of NN304 at different doses resulted in an increase in total NN304 concentration in a linear dose–response effect and a more even metabolic effect than NPH‐insulin. However, we found no clear dose–response in its metabolic effect. Diabet. Med. 16, 332–338 (1999)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-5491.1999.00081.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 158

Metadata

Authors
Heinemann, L., Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., & Heise, T.
Venue
Diabetic Medicine
Publisher
Wiley
Published
1999-04
Volume
16
Issue
4
Pages
332-338
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2012130052
Cited by
158
References
0
FWCI
4.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304. https://app.cochat.ai/papers/10.1046/j.1464-5491.1999.00081.x
The paper
Heinemann, L., Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., & Heise, T. (1999). Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.1999.00081.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.